A PHASE I/II TRIAL OF A CONDITIONALLY REPLICATION-COMPETENT ADENOVIRUS (DELTA-24-RGD) ADMINISTERED BY CONVECTION ENHANCED DELIVERY IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME.
Phase of Trial: Phase I/II
Latest Information Update: 08 Mar 2015
At a glance
- Drugs DNX 2401 (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- 22 Apr 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health NCT01582516).
- 22 Apr 2012 Additional lead trial centres and investigator identified as reported by ClinicalTrials.gov.
- 22 Apr 2012 Planned End Date changed from 28 Jul 2011 to 1 Jan 2013 as reported by ClinicalTrials.gov.